Dejgaard TF, Frandsen CS, Hansen TS et al (2016) Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
to estimate insulin sensitivity in patients treated with placebo, TZP or semaglutide after 28 weeks of treatment, achieving a hyperinsulinemic, euglycemic clamp experiment, followed by a hyperglycemic clamp (216 mg/dL) to estimate insulin secretory responses
Stacking the two can amplify blood sugar lowering more than expected
Multiple factors influence the speed and magnitude of response to GLP-1 medications
How do I know if I qualify for the GLP 1 program Wisconsin offering Wegovy or Zepbound
These include: Nausea (most common, particularly at higher doses) Vomiting Diarrhoea Constipation Decreased appetite Gastrointestinal events were generally mild to moderate in severity and tended to resolve as participants adapted to each dose level